Home » Faculty »  Hepatology »  Norah A. Terrault, M.D., M.P.H.

Norah A. Terrault, M.D., M.P.H.

Professor of Clinical Medicine & Surgery
Departments of Medicine & Surgery
Director of Viral Hepatitis Research in Liver Transplantation

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 476-2227
415-476-0659
norah.terrault@ucsf.edu
 
  • 1985 B.MSc., University of Alberta
  • 1987 M.D., University of Alberta
  • 1997 M.P.H. University of California, Berkeley
  • 1987-88 Internship, University of Toronto
  • 1988-91 Internal Medicine, University of Toronto
  • 1991-93 Gastroenterology, University of Toronto
  • 1994-95 Clinical Hepatology, Division of Gastroenterology, University of Toronto

  • 1995-97 Research Hepatology, Division of Gastroenterology, UCSF Medical Center

  • American Board of Internal Medicine, Internal Medicine
  • American Board of Internal Medicine, Gastroenterology
  • UCSF Liver Center
  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Liver Injury and Repair

Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.

Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation. 

Most recent publications from a total of 210
  1. Terrault N, Monto A, Stinchon MR, Rusie E, Moreo K. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo. J Manag Care Spec Pharm. 2015 Sep; 21(9):S1-S17. View in PubMed
  2. Dirchwolf M, Dodge JL, Gralla J, Bambha KM, Nydam T, Hung KW, Rosen HR, Feng S, Terrault NA, Biggins SW. The corrected donor age for hepatitis C virus-infected liver transplant recipients. Liver Transpl. 2015 Aug; 21(8):1022-30. View in PubMed
  3. Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51. View in PubMed
  4. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, Winston B, Redd J, Ready J, Terrault NA. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Hepatology. 2015 Sep; 62(3):715-25. View in PubMed
  5. Terrault N. Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era? Hepatology. 2015 Jul; 62(1):4-7. View in PubMed
  6. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59. View in PubMed
  7. Saxena V, Terrault NA. Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci. 2015 Apr; 60(4):806-9. View in PubMed
  8. Campos-Varela I, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, Terrault NA. Hepatitis C Genotype Influences Post-liver Transplant Outcomes. Transplantation. 2015 Apr; 99(4):835-40. View in PubMed
  9. Price JC, Terrault NA. Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in. Liver Transpl. 2015 Apr; 21(4):423-34. View in PubMed
  10. Stock PG, Terrault NA. Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology. 2015 May; 61(5):1747-54. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Norah A. Terrault, M.D., M.P.H.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X